Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-28T00:47:03.218Z Has data issue: false hasContentIssue false
  • English
  • Français

High Rate of Coadministration of Di- or Tri-valent Cation-Containing Compounds With Oral Fluoroquinolones: Risk Factors and Potential Implications

Published online by Cambridge University Press:  21 June 2016

Todd D. Barton ,
Neil O. Fishman ,
Mark G. Weiner ,
Lori A. LaRosa  and
Ebbing Lautenbach
Todd D. Barton
Affiliation:
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Neil O. Fishman
Affiliation:
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Mark G. Weiner
Affiliation:
Division of General Internal Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Lori A. LaRosa
Affiliation:
Department of Pharmacy, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Ebbing Lautenbach*
Affiliation:
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Department of Biostatistics and Epidemiology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
*
University of Pennsylvania School of Medicine, Blockley Hall, Room 825, 423 Guardian Drive, Philadelphia, PA 19104-6021[email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The characteristics of fluoroquinolone use that increase the risk of selecting for fluoroquinolone resistance remain unclear. Exposure to subtherapeutic levels of fluoroquinolone promotes bacterial development of fluoroquinolone resistance. Oral fluoroquinolone absorption is significantly impaired by coadministration with many common di- or tri-valent cation-containing compounds (DTCCs), and this interaction has been associated with therapeutic failure. However, the prevalence of, and risk factors for, in-hospital coadministration of oral fluoroquinolones with DTCCs is unknown.

Design:

Case-control study.

Setting:

A 625-bed, tertiary-care medical center.

Patients:

All inpatients who were dispensed oral levofloxacin from July 1, 1999, to June 30, 2001, were included. Coadministration was defined by documented administration of any DTCC within 2 hours of levofloxacin. Complete coadministration was defined as coadministration complicating every dose of a course of levofloxacin.

Results:

A subset of 3,227 (41.0%) of 7,871 doses of levofloxacin that occurred during the same calendar day as any DTCC was selected for further review. Overall, 1,904 (77.1%) of 2,470 doses of oral levofloxacin reviewed were complicated by coadministration with at least one DTCC. On multivariable analysis, an increased number of prescribed medications was significantly associated with complete coadministration (per increase of one medication: OR, 1.05; CI95, 1.01–1.10; P = .036), whereas patient location in an ICU was protective (OR, 0.51; CI95, 0.30–0.87; P = .013). If our prevalence results are extrapolated to all patients receiving oral levofloxacin at our hospital, approximately one in three doses was complicated by coadministration.

Conclusion:

Coadministration of fluoroquinolones with DTCCs is extremely common and significantly associated with polypharmacy.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 26 , Issue 1 , January 2005 , pp. 93 - 99
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Thomson, KS, Sanders, WE, Sanders, CC. USA resistance patterns among 18 pathogens. J Antimicrob Chemother 1994;33:9–15.Google Scholar
2.Steinman, MA, Gonzales, R, Landis, JA, Landefeld, CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003;138:525–533.Google Scholar
3.Hooper, DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998;129:908–910.Google Scholar
4.Fluit, AC, Jones, ME, Schmitz, FJ, Acar, J, Gupta, R, Verhoef, J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000;30:454–460.Google Scholar
5.Pfaller, MA, Jones, RN, Doern, GV, Kugler, K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (US and Canada, 1997). Antimicrob Agents Chemother 1998;42:1762–1770.Google Scholar
6.Neuhauser, MM, Weinstein, RA, Rydman, R, Danziger, LH, Karam, G, Quinn, JP. Antibiotic resistance among Gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885–888.Google Scholar
7.Chen, DK, McGeer, A, de Azavedo, JC, Low, DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233–239.Google Scholar
8.Lautenbach, E, Fishman, NO, Bilker, WB, et al.Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–2477.Google Scholar
9.Pena, C, Albareda, JM, Pallares, R, Pujol, M, Tubau, F, Ariza, J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520–524.Google Scholar
10.Thomas, JK, Forrest, A, Bhavnani, SM, et al.Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521–527.Google Scholar
11.Frost, RW, Lasseter, KC, Noe, AJ, Shamblen, EC, Lettieri, JT. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992;36:830–832.Google Scholar
12.Flor, S, Guay, DR, Opsahl, JA, Tack, K, Matzke, GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 1990;34:2436–2438.Google Scholar
13.Lee, LJ, Hafkin, B, Lee, ID, Hoh, J, Dix, R. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:2196–2200.Google Scholar
14.Lehto, P, Rivisto, KT, Neuvonen, PJ. The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 1994;37:82–85.Google Scholar
15.Tanigawara, Y, Nomura, H, Kagimoto, N, Okumura, K, Hori, R. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Bio Pharm Bull 1995;18:315–320.Google Scholar
16.Shiba, K, Sakai, O, Shimada, J, Okazaki, O, Aoki, H, Hakusui, H. Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992;36:2270–2274.Google Scholar
17.Polk, RE, Healy, DP, Sahai, J, Drwal, L, Rächt, E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841–1844.Google Scholar
18.Nix, DE, Watson, WA, Lener, ME, et al.Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700–705.Google Scholar
19.Guay, DR. Quinolones. In: Piscitelli, SC, Rodvold, KA eds. Drug Interactions in Infectious Diseases. Totowa, NJ: Humana Press; 2001:121–150Google Scholar
20.Noyes, M, Polk, RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med 1988;109:168–169.Google Scholar
21.Spivey, JM, Cummings, DM, Pierson, NR. Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction. Pharmacotherapy 1996;16:314–316.Google Scholar
22.Michea-Hamzehpour, M, Auckenthaler, R. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987;31:1803–1808.Google Scholar
23.Gross, R, Morgan, AS, Kinky, DE, Weiner, M, Gibson, GQ, Fishman, NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001;33:289–295.Google Scholar
24.Kleinbaum, DG, Kupper, LL, Morgenstern, H. Epidemiologie Research: Principles and Quantitative Methods. New York: Van Nostrand Reinhold; 1982.Google Scholar
25.Mantel, N, Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.Google Scholar
26.Hosmer, DO, Lemeshow, S. Applied Logistic Regression. New York: Wiley and Sons; 1989.Google Scholar
27.Sun, GW, Shook, TL, Kay, GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907–916.Google Scholar
28.Maldonado, G, Greenland, S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923–936.Google Scholar
29.Greenland, S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340–349.Google Scholar
30.Robins, JM, Greenland, S. The role of model selection in causal inference from nonexperimental data. Am J Epidemiol 1986;123:392–402.Google Scholar
31.Lomaestro, BM, Lesar, TS. Concurrent administration of ciprofloxacin and potentially interacting drugs. American Journal of Hospital Pharmacy 1989;46:1770. Letter.Google Scholar
32.Yuk, JH, Williams, TW. Drug interaction with quinolone antibiotics in intensive care unit patients. Arch Intern Med 1991;151:619. Letter.Google Scholar
33.Ortho-McNeil Pharmaceuticals. Levaquin (Levofloxacin) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceuticals; 2002.Google Scholar
34.Linjakumpu, T, Hartikainen, S, Klaukka, T, Veijola, J, Kivela, SL, Isoaho, R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809–817.Google Scholar
35.Yang, JC, Tomlinson, G, Naglie, G. Medication lists for elderly patients: clinic-derived versus in-home inspection and interview. J Gen Intern Med 2001;16:112–115.Google Scholar
36.Ebbesen, J, Buajordet, I, Erikssen, J, et al.Drug-related deaths in a department of internal medicine. Arch Intern Med 2001;161:2317–2323.Google Scholar
37.Jameson, JP, VanNoord, GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001;35:835–840.Google Scholar
38.Muir, AJ, Sanders, LL, Wilkinson, WE, Schmader, K. Reducing medication regimen complexity: a controlled trial. J Gen Intern Med 2001;16:77–82.Google Scholar
39.Fish, DN, Chow, AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101–119.Google Scholar
40.Lomaestro, BM, Bailie, GR. Quinolone-cation interactions: a review. DICP Annals of Pharmacotherapy 1991;25:1249–1258.Google Scholar
41.Leape, LL, Cullen, DJ, Clapp, MD, et al.Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999;282:267–270.Google Scholar
42.Kucukarslan, SN, Peters, M, Mlynarek, M, Nafziger, DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 2003;163:2014–2018.Google Scholar